Cannabis Science Inc. Confirms Target Indication for FDA and Prepares for Pre-IND Meeting with the FDA with its Team of FDA Specialists

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce its FDA progress resulting from the last meeting with the Company’s FDA Specialist team to officially determine that the target indication will be for a topical application for skin cancer.